To the Editor We read with interest the recent article by Calomarde-Rees et al1 on risk factors for lymphatic and hematogenous dissemination in patients with stage I and II melanoma. We agree that an improved understanding of the clinicopathological and mutation factors that relate to lymphatic and hematogenous dissemination is important to individualize surveillance strategies.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Adler NR, McArthur GA, Mar VJ. Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma. JAMA Dermatol. 2019;155(11):1322. doi:10.1001/jamadermatol.2019.2658
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.